Posts by: Patricia Inacio PhD

Patricia Inacio PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

November 30, 2018

2 Trials, Now Enrolling, Aimed at Improving Breast Cancer Prevention, Diagnosis, and Treatment

News

The University of Hawaiʻi Cancer Center is enrolling participants in two clinical trials to test new ways of preventing and diagnosing breast cancer, as well as improving current treatments. “These trials are very ... Read more

November 26, 2018

Tecentriq-Chemo Combo Under FDA Review as First-line Therapy for PD-L1-positive, Metastatic Triple-negative Breast Cancer

News

The U.S. Food and Drug Administration (FDA) is reviewing Genentech’s request for Tecentriq (atezolizumab) to be approved, in combination with the chemotherapy Abraxane (nab-paclitaxel), as a first-line treatment for certain triple-negative breast cancer patients. The supplemental Biologics License ... Read more

November 16, 2018

DoD Awards $11M for Phase 2 Trial of TPIV110 Breast Cancer Therapy

News

The U.S. Department of Defense (DoD) has awarded Mayo Clinic researchers $11 million to conduct a Phase 2 trial investigating the TPIV110 vaccine, in combination with Herceptin (trastuzumab), as a therapy ... Read more

November 7, 2018

Phase 2 Trial to Test Keytruda, Tomivosertib Combo in Triple-negative Breast Cancers

News

An upcoming Phase 2 trial will evaluate a combination of the immunotherapies Keytruda (pembrolizumab) and tomivosertib (eFT508) as a treatment for triple-negative breast cancer patients whose disease has spread to other ... Read more

October 15, 2018

First Patient Dosed in Phase 1/2 Trial of FLX475 in Breast, Other Advanced Cancers

News

The first patient has been dosed in a Phase 1/2 trial evaluating FLX Bio’s investigational therapy, FLX475, alone and in combination with the PD-1 inhibitor Keytruda (pembrolizumab), as a therapy for triple ... Read more

September 24, 2018

First Patient Dosed in Phase 1b Trial Testing Cirmtuzumab Add-on in HER2-negative Breast Cancer Patients

News

A pilot Phase 1 trial evaluating Oncternal Therapeutic’s investigational therapy cirmtuzumab as an add-on to standard chemotherapy for patients with advanced, HER2-negative breast cancer who cannot receive surgery has started dosing ... Read more

September 17, 2018

Online Test Measures Women’s Risk of Cancer Recurrence or Spread After Hormone Therapy

News

A newly developed online prognostic tool can determine whether a woman is at high risk of cancer recurrence or spread after receiving the standard five years of hormone therapy, and ... Read more

August 23, 2018August 23, 2018

Genome Analysis of DNA from Nigerian Women Leads to 1st African Breast Cancer Risk Prediction Model

News

A genome analysis of the DNA of Nigerian women uncovered a higher burden of mutations in breast cancer-related genes, which may explain why sub-Saharan African women are more likely to ... Read more

June 11, 2018

Number of Circulating Tumor Cells in Blood May Allow for Less Aggressive Treatment of Advanced Cancers

News

Using blood samples to count circulating tumor cells may help to classify metastatic breast cancer patients according to their tumors’ aggressiveness, raising the possibility of more tailored treatments, with fewer ... Read more

May 31, 2018

Potential Immunotherapy, Bria-IMT, Seen to Reduce Metastasis in Advanced Breast Cancer Patients in Trial

News

BriaCell Therapeutics‘ immunotherapy candidate Bria-IMT was found to be safe and well-tolerated, and significantly reduced the size of metastasis in two of the six breast cancer patients treated in a Phase 1/2 ... Read more